FUT4抗体

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Western blot analysis using FUT4 mouse mAb against Jurkat cell lysate.    

  
  

FUT4 antibody targets the human α-1.3-fucosyltransferase 4 (FUT4), also known as ELAM-1 ligand fucosyltransferase (ELC-1), a key enzyme in glycoconjugate biosynthesis. FUT4 catalyzes the transfer of fucose to terminal glycan structures, forming Lewis-type antigens like Lewis X (LeX) and sialyl-Lewis X (sLeX). These glycans play critical roles in cell-cell recognition, immune responses, and inflammatory processes. Notably, sLeX serves as a ligand for selectins, mediating leukocyte homing and cancer cell adhesion during metastasis. FUT4 is highly expressed in certain epithelial cancers, stem cells, and hematopoietic cells, correlating with tumor progression, drug resistance, and poor prognosis.

FUT4 antibodies are widely used in research to investigate glycosylation patterns in cancer biology, inflammation, and developmental processes. They enable detection of FUT4 expression via techniques like immunohistochemistry, flow cytometry, and Western blotting. Such studies help clarify FUT4's regulatory mechanisms in pathological conditions and its potential as a therapeutic target. Commercially available FUT4 antibodies are typically monoclonal or polyclonal, validated for specificity against recombinant or native FUT4 protein. Their applications extend to biomarker discovery and evaluating glycosylation-targeted therapies in preclinical models.